- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2050-7771
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors ; volume:8 ; number:1 ; day:26 ; month:8 ; year:2020 ; pages:1-17 ; date:12.2020
Biomarker Research ; 8, Heft 1 (26.8.2020), 1-17, 12.2020
- Creator
-
Bai, Rilan
Lv, Zheng
Xu, Dongsheng
Cui, Jiuwei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40364-020-00209-0
- URN
-
urn:nbn:de:101:1-2020101421545141995279
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:55:16+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bai, Rilan
- Lv, Zheng
- Xu, Dongsheng
- Cui, Jiuwei
- SpringerLink (Online service)
Other Objects (12)
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
Immune checkpoint inhibitors: recent progress and potential biomarkers
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
Immune checkpoint inhibitors: recent progress and potential biomarkers
Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Cancer immunotherapy beyond immune checkpoint inhibitors
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Advances in predictive biomarkers for melanoma immunotherapy
Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
Identification of bladder cancer subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
Immune checkpoint inhibitors: recent progress and potential biomarkers